Nuwellis GAAP EPS of -$5.81, revenue of $2.21M
Nuwellis reported Q3 GAAP EPS of -$5.81 and revenue of $2.21M, down 0.5% year-over-year. Net sales increased 12% sequentially and 13% year-to-date, driven by U.S. circuit and console sales growth, according to the company.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to trigger short‑term selling pressure, though the 12% sequential sales increase could provide a modest upside narrative.
Market read
Micro‑cap earnings release with negative EPS; limited broader market effect.
What to watch
Potential upside from U.S. circuit and console sales growth not fully reflected in the headline numbers.
Background
Nuwellis Inc. (NUWE) reported its Q3 2026 results, showing a GAAP loss per share of $5.81 and revenue essentially flat year‑over‑year at $2.21 million.
Ticker impact
Q3 2026 GAAP EPS of -$5.81 and revenue of $2.21M were disclosed for the first time.
likely pressure as the market prices in the weak earnings
Micro‑cap earnings surprise with negative EPS and stagnant sales typically triggers sell‑side activity.
Market effects
Minimal impact on the broader medical device sector.
Limited to U.S. micro‑cap investors.
Low
Counterpoint
If the company can turn the slight sequential sales growth into a turnaround, the dip may be overblown.
Key entities
- companyNuwellis Inc.
Medical device manufacturer reporting Q3 2026 results.
